This federal contract award, valued at $33,173.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the delivery of Tecentriq, a cancer immunotherapy medication, with a completion date of January 2, 2025. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific contract award does not have a set-aside designation, indicating open competition.
Generated 3/11/25, 9:52 AM